07:00 , May 12, 2008 |  BC Week In Review  |  Clinical News

ALS-357: Phase I/II start

Next quarter, Advanced Life Sciences will begin a dose-escalation Phase I/II trial in 12-16 patients. Advanced Life Sciences Inc. (NASDAQ:ADLS), Woodridge, Ill.   Product: ALS-357   Business: Cancer   Molecular target: NA   Description: Pentacyclic triterpenoid   Indication: Treat...
07:00 , Sep 3, 2007 |  BC Week In Review  |  Clinical News

ALS-357 regulatory update

FDA granted Orphan Drug designation for ALS-357 to treat metastatic melanoma. ADLS plan to start a Phase I/II trial of the topical pentacyclic triterpenoid early next year. Advanced Life Sciences Inc. (ADLS), Woodridge, Ill.   Product:...
07:00 , Sep 18, 2006 |  BC Week In Review  |  Clinical News

ALS-357: Phase I/II start

Next year, ADLS will start an open-label Phase I/II trial in 16 patients with unresectable metastatic melanoma. Advanced Life Sciences Inc. (ADLS), Woodridge, Ill.   Product: ALS-357   Business: Cancer   Molecular target: NA   Description: Pentacyclic triterpenoid...